18 results about "CDC42" patented technology

The invention belongs to the field of biology, and discloses a cdc42 gene knockout HCT-8 cell line and application thereof, the taxonomic name of the cdc42 gene knockout HCT-8 cell line is Homo sapiens, the cdc42 gene knockout HCT-8 cell line is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC NO: 66616; the preservation date is July 01, 2025; the preservation address is the fifth floor of building 59, No.100 courtyard, Xianlie Middle Road, Guangzhou City, Guangdong Province. According to the invention, a cdc42 gene in an HCT-8 cell is knocked out by adopting a CRISPR-Cas9 technology so as to construct a cdc42 gene knocked-out HCT-8 cell line, and the cdc42 gene knocked-out HCT-8 cell line is used as a cryptosporidium parvum cell infection model.

The invention belongs to the technical field of biomolecular markers, and particularly relates to a cross-animal general skeleton-derived hematopoietic stem cell marker gene set and a screening method thereof. According to the invention, a bone-derived hematopoietic stem cell marker gene set universal across animal categories is constructed for the first time, and the bone-derived hematopoietic stem cell marker gene set comprises at least five of Cdc42, Cbx, Tfam, Denr, Mcts1, Ak2, Ruvbl, Ahcy, Nna and Vdac; the hematopoietic stem cell marker gene set is obtained through cross-species homologous gene screening, the defect that a traditional vertebrate marker has no orthohomology in invertebrates is overcome, accurate recognition of HSC in shells is achieved, the hematopoietic stem cell marker gene set has species universality and cell specificity, the immune state of aquatic animals can be evaluated, disease-resistant breeding can be guided, and the application prospect is wide. And molecular evidence is provided for analyzing an evolution path of a hematopoietic system from invertebrates to vertebrates.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

A molecular marker related to a differential expression of a pregnancy stage of sheep and application thereof is provided, the molecular marker is oar-miR-29a miRNA target gene, and a sequence is as follows: 5′-UAGCACCAUUUGAAAUCAGUGUU-3′ shown in SEQ ID NO: 12; the oar-miR-29a miRNA related to the pregnancy stage of sheep was screened and identified, through further experimental verification, the relationship between oar-miR-29a and CDC42 was found, which provided important clues for understanding the mechanism of miRNA regulatory network in the process of sheep pregnancy, it can be applied to regulate the uterine receptivity of sheep to improve the reproductive efficiency, and it can also be used as a molecular marker to optimize the breeding direction, cultivate new varieties or to make a 50K chip dedicated to Hu sheep.

The present invention provides the use of Caspase8 in the preparation of a medicament for non-alcoholic fatty liver disease. Overexpression of Caspase8 inhibits the development of non-alcoholic fatty liver disease. The present invention identifies a specific role of Caspase8 in non-alcoholic fatty liver disease: decreased Caspase8 expression in hepatic macrophages activates the Cflip / ELK4 / Psap signaling pathway, leading to macrophage polarization toward the M1 type. This, in turn, activates the Rac1 / cdc42 / JNK signaling pathway within hepatocytes through the Gpr37I1 receptor on the hepatocyte surface, leading to increased lipid deposition in hepatocytes. Caspase8 or its small molecule analogs may offer hope for the treatment of steatohepatitis.

The present invention discloses a specific antibody for acetylation at the CDC42-K153 site, a preparation method and an application thereof, and relates to the field of biotechnology. The amino acid sequence of the antibody is shown in SEQ ID NO: 1; the preparation method thereof is as follows: a CDC42-K153 peptide segment DLKAVKYVECSALTQKGL is prepared by a synthetic method, and the nucleotide sequence thereof is shown in SEQ ID NO: 2; and an acetylated modified peptide segment is obtained, and a peptide segment without an acetylated group is used as a control peptide segment. The acetylated modified peptide segment is immunized with New Zealand white rabbits to produce a site-specific acetylated polyclonal antibody and obtain an antiserum; the application of the specific antibody for acetylation at the K153 site in determining the expression level of acetylation at K153 of CDC42. The present invention develops a specific antibody for acetylation at the K153 site, which is applied to the determination of acetylated antigens at the K153 site of the CDC42 protein, and has good specificity and sensitivity.

The present disclosure relates to compounds of the formulae herein (e.g, Formula (II)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, which are inhibitors of a GTPase (e.g., cell division control protein 42 homolog (Cdc42)). The present disclosure also provides pharmaceutical compositions comprising the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating diseases (e.g., malignant neoplastic diseases, diseases associated with aging) by administering to a subject in need thereof the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof.

The present invention relates to a bivalent, bispecific monoclonal antibody (bbmAb) or a variant thereof for use in treating or alleviating symptoms of autoinflammatory or disease-related conditions in subjects requiring such treatment or elimination of CDC42 mutations or XIAP deficiency.

An inhibitor of the Rho GTPase Cdc42 is proposed for use in the prevention and / or treatment of Parkinson's disease in humans or animals. In a mouse model where the mice were genetically modified to accumulate α-synuclein and develop Parkinson's disease, administration of a Cdc42 inhibitor to the affected mice reduced α-synuclein accumulation, improved Parkinson's disease symptoms, increased mean lifespan, and extended overall lifespan. Minimal to no adverse effects were observed in the affected mice.

The invention discloses a fusarium venanii strain with high substrate conversion rate and low RNA (Ribonucleic Acid) content and application of the fusarium venanii strain, and belongs to the fields of genetic engineering technology and food biotechnology. Compared with a wild strain, the fusarium venanii Fcdc has the advantages that the conversion rate of a gene Cdc42 on a genome from a substrate to thallus is increased to 67.06%, the conversion rate from the substrate to protein is increased to 26.01%, the sugar consumption for producing mycelia with the same dry weight is reduced by 60%-70%, the sugar consumption for producing mycelia protein with the same dry weight is reduced by 60%-70% compared with the wild strain, and the RNA content of the mycelia is reduced by more than 90% and is as low as 0.32% compared with the wild strain; the method has the advantages that the method is simple and convenient to operate, a heat treatment and nucleic acid removal step is not needed, the production efficiency and the safety quality of the fusarium venanii hypha protein are obviously improved, the production cost is reduced, and the fusarium venanii can be used for further developing genetic engineering modification work and cultivating fusarium venanii strains with high protein content and low RNA content.

The present disclosure relates to a modified peptide including (i) an amino acid sequence (X)-GRT-(Y)-TLC-(Z), or (ii) an amino acid sequence having at least 40% sequence identity to the amino acid sequence (X)-GRT-(Y)-TLC-(Z), wherein X, Y, and Z are the same as described in the specification. In this regard, methods for inhibiting the activity of at least one enzyme selected from the group consisting of AKT1 (PKB alpha), AKT2 (PKB beta), MAP3K8 (COT), MST4, AURKB (Aurora B), ROCK1, RPS6KB1 (p70S6K), CDC42 BPA (MRCKA), BRAF, RAFI (cRAF) Y340D Y341D, SGK (SGK1), MAP4K4 (HGK), AURKA (Aurora A), AURKC (Aurora C), BRAF V599E, CHEK1 (CHK1), GSG2 (Haspin), CHEK2 (CHK2), FGR, IKBKB (IKK beta), CDK7 / cyclin H / MNAT1, and CDC42 BPB (MRCKB) and Ab!; and inhibiting cell proliferation are also provided, as are methods for preventing or treating cancer or a neurodegenerative disease or disorder.

The invention relates to an inhibitor of Rho GTPase Cdc42 for use in the prevention and / or treatment of Parkinson's disease of the human or animal body. In a mouse model in which the mice were genetically modified to accumulate α-synuclein and develop Parkinson's disease, it has been shown that the administration of a Cdc42 inhibitor in the diseased mice reduces the accumulation of α-synuclein, improves the symptoms of Parkinson's disease, increases the average life expectancy, and prolongs the total life span. Only minimal to no side effects occurred in the diseased mice.

The invention provides a Cdc42 active probe based on a self-labeling enzyme TMP-tag3 and an application of the Cdc42 active probe. According to the invention, the monitoring of the Cdc42 activity on the living cell population level is realized, and the dynamic visualization of the Cdc42 activity on the single cell level and the subcellular level with high temporal-spatial resolution is realized. On the living cell population level, spectrum displacement which is 12 nm different from that of a positive control group and about 4 times of light intensity change are achieved, response is very obvious, and after Cdc42 specific GEFs and RhoGDI are added for regulation and control, the spectrum of the probe moves in the corresponding expected direction, which indicates that related signal channels in cells are not damaged due to introduction of exogenous Cdc42. Clear division of the Cdc42WT and the positive control group Cdc42CA is realized on the single cell level. On the subcellular level, the probe can detect different subcellular localization Cdc42 molecular activity in long-term imaging.

The invention discloses an SNP molecular marker based on CDC42 gene and related to pig hypoxia resistance and application of the SNP molecular marker, the SNP molecular marker is located at the 359th site of a nucleotide sequence of a core promoter region of the CDC42 gene, the basic group is G or T, and T is a dominant allele under the hypoxia condition; and the nucleotide sequence of the core promoter region of the CDC42 gene is-1bp to-619bp of the sequence as shown in SEQ ID NO. 15. Through high and low altitude transcriptome analysis of Tibetan pigs and a pig skeletal muscle satellite cell hypoxia model, it is found that the CDC42 gene plays an important role in pig hypoxia resistance, and a CDC42 gene promoter region is utilized to construct a dual-fluorescein reporter vector to determine the SNP site (g.-359Ggt; t). The invention provides the SNP molecular marker to assist the breeding method of the hypoxia-resistant pig breeds, a large amount of group scale sampling and determination are not needed, and the breeding efficiency of the hypoxia-resistant pig breeds is effectively improved.

The present invention relates to a bivalent bispecific monoclonal antibody (bbmAb), or a variant thereof, for use in treating or alleviating symptoms of a self-inflammation or disease based on CDC42 mutation or XIAP deficiency in a subject in need thereof.

The invention belongs to the biological field and discloses a cdc42 Gene knockout HCT-8 cell line and its application, cdc42 The taxonomic name of the knockout HCT-8 cell line is Homo sapiens , deposited in Guangdong Provincial Microbial Culture Collection Center, with the deposit number GDMCC NO: 66616; deposit date July 1, 2025; deposit address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province. The present invention uses CRISPR-Cas9 technology to knock out HCT-8 cells cdc42 Gene to construct cdc42 The gene-knockout HCT-8 cell line was used as a model for Cryptosporidium parvum cell infection.

The application discloses a strain of Fusarium venenatum with high substrate conversion rate and low RNA content and an application thereof, and belongs to the field of genetic engineering technology and food biotechnology. Cdc42 Compared with the wild type, the Fusarium venenatum Fcdc has the following advantages: the substrate conversion rate is increased to 67.06%, the substrate to protein conversion rate is increased to 26.01%, the sugar consumption for producing the same dry weight of mycelium is reduced by 60%-70%, the sugar consumption for producing the same dry weight of mycelium protein is reduced by 60%-70% compared with the wild type, the RNA content of the mycelium is reduced by more than 90% compared with the wild type strain, is as low as 0.32%, and the step of removing nucleic acid by heat treatment is not needed, so that the production efficiency and safety quality of the mycelium protein of the Fusarium venenatum are significantly improved, the production cost is reduced, the Fusarium venenatum can be further used for genetic engineering modification work, and a Fusarium venenatum strain with high protein content and low RNA content is cultivated.